Earning Analysis
Welcome to our in-depth analysis of United Therapeutics Corp(UTHR) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of United Therapeutics Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-29 | Pre-Market | 6.89 | 7.16 | +3.92 | 812.87M | 799.50M | -1.65 | +9.63 | +5.61 |
| FY2025Q2 | 2025-07-30 | Pre-Market | 6.80 | 6.41 | -5.74 | 803.65M | 798.60M | -0.63 | -5.25 | -1.65 |
| FY2025Q1 | 2025-04-30 | Pre-Market | 6.29 | 6.63 | +5.41 | 729.32M | 794.40M | +8.92 | +0.77 | -0.68 |
| FY2024Q4 | 2025-02-26 | Pre-Market | 6.10 | 6.19 | +1.48 | 734.74M | 735.90M | +0.16 | -10.80 | -13.68 |
| FY2024Q3 | 2024-10-30 | Pre-Market | 6.16 | 6.39 | +3.73 | 722.57M | 748.90M | +3.64 | +2.44 | +8.49 |
| FY2024Q2 | 2024-07-31 | - | 6.33 | 5.85 | -7.58 | 691.87M | 714.90M | +3.33 | -7.18 | -4.62 |
| FY2024Q1 | 2024-05-01 | - | 5.63 | 6.17 | +9.59 | 624.19M | 677.70M | +8.57 | +8.88 | +13.61 |
| FY2023Q4 | 2024-02-21 | - | 3.92 | 4.36 | +11.22 | 575.87M | 614.70M | +6.74 | +2.34 | +5.88 |
| FY2023Q3 | 2023-11-01 | - | 4.89 | 5.38 | +10.02 | 585.82M | 609.40M | +4.03 | +0.55 | +3.40 |
| FY2023Q2 | 2023-08-02 | - | 4.41 | 5.24 | +18.82 | 524.17M | 596.50M | +13.80 | +0.30 | -1.40 |
UTHR Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, United Therapeutics Corp reported performance for FY2025Q3, announced on 2025-10-29. The company achieved an EPS of 7.16, compared to analyst estimates of 6.89 by 3.92% . Revenue for the quarter reached 799.50M compared to expectations of 812.87M by -1.65% .
The stock price reacted with a 9.63% one-day change and a 5.61% five-day change following the earnings release. These movements reflect market reaction in United Therapeutics Corp growth trajectory and strategic initiatives.
UTHR Earnings Forecast
Looking ahead, United Therapeutics Corp(UTHR) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 818.74M and an EPS of 6.88.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -0.26%, while EPS estimates have been Revise Upward by 2.33%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 1.96% . These revisions correlate with a 20.87% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in United Therapeutics Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between UTHR's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
-0.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.33%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+1.96%
In Past 3 Month
Stock Price
Go Up
+20.87%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:3.21B
--
EPS Estimate-Annual FY 2025:27.10
—
Stock Price484.10
UTHR Revenue and EPS Performance: A Historical Perspective
United Therapeutics Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-29,Pre-Market):
EPS: 7.16 (Actual) vs.6.89 (Estimate) (3.92%)
Revenue: 799.50M (Actual) vs. 812.87M (Estimate) (-1.65%)
Price Reaction: 9.63%(1-Day), 5.61%(5-Day)
FY2025Q2 (2025-07-30,Pre-Market):
EPS: 6.41 (Actual) vs.6.80 (Estimate) (-5.74%)
Revenue: 798.60M (Actual) vs. 803.65M (Estimate) (-0.63%)
Price Reaction: -5.25%(1-Day), -1.65%(5-Day)
FY2025Q1 (2025-04-30,Pre-Market):
EPS: 6.63 (Actual) vs.6.29 (Estimate) (5.41%)
Revenue: 794.40M (Actual) vs. 729.32M (Estimate) (8.92%)
Price Reaction: 0.77%(1-Day), -0.68%(5-Day)
Earnings Reaction
The chart below shows how UTHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, UTHR sees a +0.72% change in stock price 10 days leading up to the earnings, and a +3.37% change 10 days following the report. On the earnings day itself, the stock moves by +0.17%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -0.39% on the day following the earnings release and then changed by 1.37% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Summary
Positive
2025-10-29
The earnings call presented solid financial performance with 7% revenue growth and strong Tyvaso sales. Product development is advancing with promising trials and new product launches. Share repurchases show confidence in financial health. Despite uncertainties in market dynamics and strategic execution risks, management expressed optimism about growth opportunities and partnerships. Analysts showed interest in the company's plans, and no negative sentiment was evident in the Q&A. The overall sentiment is positive, with potential for a stock price increase of 2% to 8% over the next two weeks.
United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Summary
Positive
2025-07-30
The earnings call reflects strong financial performance with record revenue and growth in key products like Tyvaso DPI. The Q&A section reveals confidence in ongoing trials and a robust share repurchase plan, indicating management's belief in the company's future prospects. While there were some unanswered questions, overall sentiment remains positive, driven by strong financials and optimistic guidance.
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Summary
Positive
2025-04-30
The company showed strong financial performance with record revenue growth of 24% and robust cash flow. Positive developments in product pipelines and strategic acquisitions further bolster future prospects. Share repurchase and disciplined financial management are favorable. Regulatory and competitive pressures pose risks, but optimistic guidance and strategic investments suggest a positive outlook. Given these factors, a stock price increase of 2% to 8% is likely.
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Summary
Positive
2025-04-30
The earnings call shows strong financial performance with a 17% revenue growth and robust operating cash flow. Product development and market strategy are promising, with continued innovation and confidence in maintaining growth despite competition. Regulatory and competitive risks exist, but the company is addressing supply chain challenges and investing in future capabilities. The significant share repurchase program supports a positive sentiment. The Q&A section reveals some management evasiveness, but overall, the outlook remains positive, with expected double-digit revenue growth and strategic investments.
United Therapeutics Corp (UTHR) Q4 2024 Earnings Call Summary
Positive
2025-02-26
The earnings call highlights strong financial performance with record revenues, robust shareholder returns, and optimistic future growth expectations. Despite some regulatory and competitive challenges, the company is investing in product development and expanding its market presence. The Q&A session did not reveal significant negative sentiment from analysts, and management's optimistic guidance further supports a positive outlook. Overall, the combination of strong earnings, optimistic guidance, and shareholder returns suggests a positive stock price movement over the next two weeks.
United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Summary
Positive
2024-10-30
The earnings call highlights strong financial performance with record revenues and significant growth across key products like Tyvaso and Orenitram. The completion of a $1 billion share repurchase program and a healthy financial position further support a positive outlook. Despite some regulatory and competitive risks, optimistic guidance and the potential for future revenue growth suggest a positive sentiment. The Q&A session did not reveal major concerns, maintaining the overall positive sentiment.
United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Summary
Positive
2024-07-31
The earnings call highlights strong financial performance with record revenues and substantial growth in key products like Tyvaso. Despite uncertainties in clinical trials and regulatory approvals, the company shows optimism in its strategic initiatives, including xenotransplantation. The Q&A reveals positive analyst sentiment towards current growth drivers. However, the lack of new share repurchase or dividend announcements slightly tempers the outlook. Overall, the robust revenue growth and optimistic guidance suggest a positive stock price movement in the short term.
People Also Watch
FAQ
What were the key highlights of UTHR’s latest earnings report for FY2025Q3?
How did UTHR’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for UTHR for 2025/Q4?
How does UTHR’s stock price correlate with earnings forecast revisions?
What should investors expect from UTHR’s next earnings report?